120444-71-5 Usage
Uses
Used in Pharmaceutical Research:
Deramciclane was investigated as a potential anxiolytic and antipsychotic agent for the treatment of schizophrenia and Alzheimer's disease. It was used as a research compound for understanding its effects on the serotonin, dopamine, and adrenergic receptor systems, which are implicated in these conditions.
Used in Clinical Trials:
In the past, Deramciclane was used as a test drug in clinical trials to assess its efficacy in treating generalized anxiety disorders. The trials aimed to evaluate its potential as a non-benzodiazepine anxiolytic and antipsychotic medication, but the results led to the discontinuation of its clinical development due to insufficient efficacy.
Note: Since Deramciclane's clinical development was halted and it is no longer actively researched or sold as a medicinal product, there are no current applications in different industries. The uses mentioned above are historical and pertain to its past research and development stages.
Check Digit Verification of cas no
The CAS Registry Mumber 120444-71-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,4,4 and 4 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 120444-71:
(8*1)+(7*2)+(6*0)+(5*4)+(4*4)+(3*4)+(2*7)+(1*1)=85
85 % 10 = 5
So 120444-71-5 is a valid CAS Registry Number.
InChI:InChI=1/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1
120444-71-5Relevant articles and documents
High purity (1R,2S,4R)-(-)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof
-
Example 2, (2010/11/29)
The invention relates to high purity (1R,2S,4R)-(?)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2′-{N,N